Just under a year and a half after being spun off from Evotec AG, Germany's Topas Therapeutics GMBH has signed a deal with Eli Lilly & Co. in the field of antigen-specific tolerance induction.
The multi-year collaboration will have an initial focus on external antigens thought to induce inflammation and/or autoimmune disease. Topas will...








